Kidney Cancer Trial, Recruiting NCT06882486 Sponsor: Institut Paoli-Calmettes Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT06882486
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have been diagnosed with kidney cancer that has spread to other parts of your body at the same time as the original diagnosis (called synchronous metastatic kidney cancer)
  • Your original kidney tumor has not been surgically removed yet
  • You have already received a type of cancer treatment called immunotherapy (specifically a combination therapy involving immune checkpoint inhibitors)
  • Your cancer has shown a very strong response to treatment — either completely disappeared or shrunk by more than 75% in the areas where it had spread (not counting the original kidney tumor)
  • You are willing and able to sign a consent form to participate in the trial
  • You are covered by the French national social security system or an equivalent scheme

Who may not be able to join:

  • Women who are pregnant, possibly pregnant without using effective contraception, or who are breastfeeding
  • People who are in an emergency medical situation or are unable to give their own consent
  • Adults who are under legal protection, such as those with a court-appointed guardian or similar arrangement
  • People who are unable to attend regular medical check-ups due to where they live, their social situation, or their mental health
  • People who have already had their kidney surgically removed as part of cancer treatment
  • People being considered for kidney removal only because of symptoms, but whose cancer spreading to other areas has not responded strongly to treatment
  • People whose kidney cancer had not spread at the time of diagnosis and who received immunotherapy before surgery in that context
  • People who are not medically suitable for surgery or cannot have their kidney removed for health reasons
  • People who do not wish to have their kidney surgically removed
  • People with severe, advanced kidney failure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut Paoli-Calmettes
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 April 2031

Where this trial is recruiting

🇫🇷 France

Primary endpoints

progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov